Nanterinone

CAS No. 102791-47-9

Nanterinone( —— )

Catalog No. M34663 CAS No. 102791-47-9

Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 217 Get Quote
5MG 342 Get Quote
10MG 504 Get Quote
25MG 790 Get Quote
50MG 1086 Get Quote
100MG 1431 Get Quote
500MG 2871 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Nanterinone
  • Note
    Research use only, not for human use.
  • Brief Description
    Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.
  • Description
    Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    102791-47-9
  • Formula Weight
    253.3
  • Molecular Formula
    C15H15N3O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1N(C=C(C)N1)C=2C=C3C(=C(C)C2)NC(=O)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Remme WJ, et al. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. Cardiovasc Drugs Ther. 1996 May;10(2):137-44.?
molnova catalog
related products
  • Anagrelide

    Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.

  • BI-409306

    BI-409306 is a potent and selective inhibitor of PDE9A (IC50 of 52 nM),and can be used in the research of memory.

  • Siguazodan

    Siguazodan is an effective, selective, orally active phosphodiesterase III ((PDE-III)) inhibitor with an IC50 of 117 nM.